Farhad Ravandi-Kashani, MD

Articles by Farhad Ravandi-Kashani, MD

Rationale for Phase I Study of AMG 330 in Relapsed/Refractory AML

December 10th 2018

<br /> Farhad Ravandi-Kashani, MD, The University of Texas MD Anderson Cancer Center, discusses the rationale for targeting CD33 with AMG 330 in patients with relapsed/refractory acute myeloid leukemia.

Latest Updated Articles

$Rationale for Phase I Study of AMG 330 in Relapsed/Refractory AML$
Rationale for Phase I Study of AMG 330 in Relapsed/Refractory AML
Published: December 10th 2018 | Updated: